ClinicalTrials.Veeva

Menu

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

M

MBQ Pharma

Status and phase

Enrolling
Phase 1

Conditions

Breast Cancer Stage IV
Breast Cancer
Breast Neoplasm

Treatments

Drug: MBQ-167

Study type

Interventional

Funder types

Industry
Other U.S. Federal agency

Identifiers

NCT06075810
MBQ-ABC001
CDMRP-BC220292 (Other Grant/Funding Number)

Details and patient eligibility

About

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Full description

The main questions this clinical trial aims to answer are:

  • What, if any, are the side effects of different dose levels in humans?
  • What is the maximum tolerated dose?
  • How does the human body process the drug?
  • Does the drug slow, stop or eliminate cancer in human participants?

Participants will be asked to:

  • provide informed consent
  • be evaluated by physicians and provide laboratory specimens to determine if eligible
  • take MBQ-167 orally twice a day for at least 21 days
  • may continue dosing, if safe to do so, until not effective or other decision to stop is made
  • participate in multiple visits that include additional evaluations, laboratory tests and diary review until after stopping the investigational drug

Enrollment

48 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
  • Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.
  • Participants with known brain metastases may be eligible if specific conditions are met.
  • Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.
  • Are able to swallow capsules twice daily with a meal.

Key Exclusion Criteria:

  • The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.
  • Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.
  • Females who are pregnant or breastfeeding.
  • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
  • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
  • Active malignancies other than advanced breast cancer will be excluded from the study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

48 participants in 1 patient group

MBQ-167 oral capsule
Experimental group
Description:
A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design
Treatment:
Drug: MBQ-167

Trial contacts and locations

4

Loading...

Central trial contact

Jose Rodriguez-Orengo, PhD; Scott Houston

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems